The medical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s exhibiting significant efficacy in clinical trials for treating obesity. Unlike some available weight loss approaches, retatrutide appears to provide a more substantial reduction